Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omalizumab

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xolair

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluticasone Propionate

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Optinose

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 08, 2020

            Details:

            Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.

            ALK

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ciprofloxacin

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Otiprio

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Otonomy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 17, 2020

            Details:

            Under the terms of the agreement, ALK will have exclusive rights to promote OTIPRIO for AOE to office-based healthcare professionals in the U.S. including ENT physicians, pediatricians and select primary care physicians.